{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:58:55Z","timestamp":1772215135638,"version":"3.50.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01759-6","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:51:31Z","timestamp":1772207491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Role of Bispecific Antibodies in Precision Medicine, Cancer and Modern Therapeutics"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7282-9406","authenticated-orcid":false,"given":"Muhammad Faisal","family":"Shahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5899-1933","authenticated-orcid":false,"given":"Samra","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"1759_CR1","unstructured":"Ehrlich P. Aus theorie und praxis der chemotherapie. W. Klinkhardt; 1911."},{"key":"1759_CR2","unstructured":"Behring Ev. Ueber das zustandekommen der diphtherie-immunit\u00e4t und der tetanus-immunit\u00e4t bei thieren. Drucke 19. Jh., 1890."},{"issue":"3565","key":"1759_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.140.3565.405.a","volume":"140","author":"NK Jerne","year":"1963","unstructured":"Jerne NK, Nordin AA. Plaque formation in agar by single antibody-producing cells. Science. 1963;140(3565):405\u2013405.","journal-title":"Science"},{"issue":"5517","key":"1759_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495\u20137.","journal-title":"Nature"},{"key":"1759_CR5","doi-asserted-by":"crossref","unstructured":"Houen G. Therapeutic antibodies: an overview. Therapeutic Antibodies: Methods and Protocols, 2022: pp. 1\u201325.","DOI":"10.1007\/978-1-0716-1450-1_1"},{"key":"1759_CR6","unstructured":"Society TA. Therapeutic monoclonal antibodies approved or in regulatory review.. [cited 2024 September 25]; Available from: www.antibodysociety.org\/antibody-therapeutics-product-data"},{"issue":"16","key":"1759_CR7","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","volume":"85","author":"JS Huston","year":"1988","unstructured":"Huston JS, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988;85(16):5879\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1759_CR8","doi-asserted-by":"publisher","first-page":"626616","DOI":"10.3389\/fimmu.2021.626616","volume":"12","author":"J Ma","year":"2021","unstructured":"Ma J, et al. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616.","journal-title":"Front Immunol"},{"issue":"4","key":"1759_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41584-019-0188-8","volume":"15","author":"AS Schmid","year":"2019","unstructured":"Schmid AS, Neri D. Advances in antibody engineering for rheumatic diseases. Nat Rev Rheumatol. 2019;15(4):197\u2013207.","journal-title":"Nat Rev Rheumatol"},{"issue":"31","key":"1759_CR10","doi-asserted-by":"publisher","first-page":"10662","DOI":"10.1074\/jbc.RA120.013638","volume":"295","author":"R Abskharon","year":"2020","unstructured":"Abskharon R, et al. Crystal structure of a conformational antibody that binds Tau oligomers and inhibits pathological seeding by extracts from donors with alzheimer\u2019s disease. J Biol Chem. 2020;295(31):10662\u201376.","journal-title":"J Biol Chem"},{"issue":"5","key":"1759_CR11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1006\/jmbi.1997.1508","volume":"275","author":"LJ Harris","year":"1998","unstructured":"Harris LJ, Skaletsky E, McPherson A. Crystallographic structure of an intact IgG1 monoclonal antibody11Edited by I. A. Wilson. J Mol Biol. 1998;275(5):861\u201372.","journal-title":"J Mol Biol"},{"issue":"1","key":"1759_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/antib5010006","volume":"5","author":"AR Root","year":"2016","unstructured":"Root AR, et al. Development of PF-06671008, a highly potent Anti-P-cadherin\/Anti-CD3 bispecific DART molecule with extended Half-Life for the treatment of cancer. Antibodies. 2016;5(1):6.","journal-title":"Antibodies"},{"key":"1759_CR13","unstructured":"FDA. 2018 [cited 2024 September 23]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-blinatumomab-blincyto-amgen-inc-treatment-adult-and-pediatric#:~:text=acute%20lymphoblastic%20leukemia-,FDA%20granted%20accelerated%20approval%20to%20blinatumomab%20(Blincyto%2C%20Amgen%20Inc.,cell%20precursor%20acute%20lymphoblastic%20leukemia&text=On%20March%2029%2C%202018%2C%20the,(Blincyto%2C%20Amgen%20Inc.)."},{"issue":"1","key":"1759_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib11010016","volume":"11","author":"R Tavarozzi","year":"2022","unstructured":"Tavarozzi R, Manzato E. The role of bispecific antibodies in non-hodgkin\u2019s lymphoma: from structure to prospective clinical use. Antibodies. 2022;11(1):16.","journal-title":"Antibodies"},{"key":"1759_CR15","doi-asserted-by":"publisher","first-page":"215699","DOI":"10.1016\/j.canlet.2022.215699","volume":"538","author":"G Xu","year":"2022","unstructured":"Xu G, et al. Therapeutic bispecific antibodies against intracellular tumor antigens. Cancer Lett. 2022;538:215699.","journal-title":"Cancer Lett"},{"issue":"7","key":"1759_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"JB Ridgway","year":"1996","unstructured":"Ridgway JB, Presta LG, Carter P. Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng Des Sel. 1996;9(7):617\u201321.","journal-title":"Protein Eng Des Sel"},{"key":"1759_CR17","doi-asserted-by":"crossref","unstructured":"Xu Y, et al. Production of bispecific antibodies in knobs-into-holes using a cell-free expression system. MAbs. Taylor & Francis; 2015.","DOI":"10.4161\/19420862.2015.989013"},{"issue":"7","key":"1759_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt0798-677","volume":"16","author":"AM Merchant","year":"1998","unstructured":"Merchant AM, et al. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16(7):677\u201381.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1759_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/protein\/gzp094","volume":"23","author":"JH Davis","year":"2010","unstructured":"Davis JH, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel. 2010;23(4):195\u2013202.","journal-title":"Protein Eng Des Sel"},{"issue":"35","key":"1759_CR20","doi-asserted-by":"publisher","first-page":"14706","DOI":"10.1074\/jbc.M117.793497","volume":"292","author":"C De Nardis","year":"2017","unstructured":"De Nardis C, et al. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human Immunoglobulin G1. J Biol Chem. 2017;292(35):14706\u201317.","journal-title":"J Biol Chem"},{"issue":"2","key":"1759_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nbt.2797","volume":"32","author":"SM Lewis","year":"2014","unstructured":"Lewis SM, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal fab interface. Nat Biotechnol. 2014;32(2):191\u20138.","journal-title":"Nat Biotechnol"},{"key":"1759_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ymeth.2018.10.005","volume":"154","author":"H Shiraiwa","year":"2019","unstructured":"Shiraiwa H, et al. Engineering a bispecific antibody with a common light chain: identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974. Methods. 2019;154:10\u201320.","journal-title":"Methods"},{"issue":"410","key":"1759_CR23","doi-asserted-by":"publisher","first-page":"eaal4291","DOI":"10.1126\/scitranslmed.aal4291","volume":"9","author":"T Ishiguro","year":"2017","unstructured":"Ishiguro T, et al. An anti\u2013glypican 3\/CD3 bispecific T cell\u2013redirecting antibody for treatment of solid tumors. Sci Transl Med. 2017;9(410):eaal4291.","journal-title":"Sci Transl Med"},{"issue":"5844","key":"1759_CR24","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1144603","volume":"317","author":"DN Van Kolfschoten","year":"2007","unstructured":"Van Kolfschoten DN. Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange. Science. 2007;317(5844):1554\u20137.","journal-title":"Science"},{"key":"1759_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-1-61779-921-1_9","volume-title":"Therapeutic Proteins: Methods and Protocols","author":"E DiGiammarino","year":"2012","unstructured":"DiGiammarino E, Ghayur T, Liu J. Design and generation of DVD-Ig\u2122 molecules for dual-specific targeting. In: Therapeutic Proteins: Methods and Protocols. 2012. p. 145\u201356."},{"issue":"11","key":"1759_CR26","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nbt1345","volume":"25","author":"C Wu","year":"2007","unstructured":"Wu C, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain Immunoglobulin. Nat Biotechnol. 2007;25(11):1290\u20137.","journal-title":"Nat Biotechnol"},{"issue":"27","key":"1759_CR27","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1073\/pnas.1019002108","volume":"108","author":"W Schaefer","year":"2011","unstructured":"Schaefer W, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci. 2011;108(27):11187\u201392.","journal-title":"Proc Natl Acad Sci"},{"key":"1759_CR28","doi-asserted-by":"crossref","unstructured":"Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi-and multispecific antibodies. in MAbs. 2016. Taylor & Francis.","DOI":"10.1080\/19420862.2016.1197457"},{"issue":"7\u20138","key":"1759_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/protein\/gzy021","volume":"31","author":"JT Regula","year":"2018","unstructured":"Regula JT, et al. Variable heavy\u2013variable light domain and Fab-arm crossmabs with charged residue exchanges to enforce correct light chain assembly. Protein Eng Des Selection. 2018;31(7\u20138):289\u201399.","journal-title":"Protein Eng Des Selection"},{"issue":"8","key":"1759_CR30","doi-asserted-by":"publisher","first-page":"e0183390","DOI":"10.1371\/journal.pone.0183390","volume":"12","author":"SL Ross","year":"2017","unstructured":"Ross SL, et al. Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing. PLoS One. 2017;12(8):e0183390.","journal-title":"PLoS One"},{"issue":"11","key":"1759_CR31","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1158\/1078-0432.CCR-17-2265","volume":"24","author":"O Campagne","year":"2018","unstructured":"Campagne O, et al. Integrated pharmacokinetic\/pharmacodynamic model of a bispecific CD3xCD123 DART molecule in nonhuman primates: evaluation of activity and impact of immunogenicity. Clin Cancer Res. 2018;24(11):2631\u201341.","journal-title":"Clin Cancer Res"},{"issue":"289","key":"1759_CR32","doi-asserted-by":"publisher","first-page":"ra28982","DOI":"10.1126\/scitranslmed.aaa5693","volume":"7","author":"GR Chichili","year":"2015","unstructured":"Chichili GR, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015;7(289):ra28982\u201328982.","journal-title":"Sci Transl Med"},{"key":"1759_CR33","doi-asserted-by":"crossref","unstructured":"Wu X et al. Protein design of IgG\/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. in MAbs. 2015. Taylor & Francis.","DOI":"10.1080\/19420862.2015.1007826"},{"issue":"1","key":"1759_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/jmbi.1999.3156","volume":"293","author":"SM Kipriyanov","year":"1999","unstructured":"Kipriyanov SM, et al. Bispecific tandem Diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol. 1999;293(1):41\u201356.","journal-title":"J Mol Biol"},{"key":"1759_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0651-0","volume":"17","author":"M Van Roy","year":"2015","unstructured":"Van Roy M, et al. The preclinical Pharmacology of the high affinity anti-IL-6R Nanobody\u00ae ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Therapy. 2015;17:1\u201316.","journal-title":"Arthritis Res Therapy"},{"issue":"5","key":"1759_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"issue":"16Supplement","key":"1759_CR37","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/1538-7445.AM2020-2270","volume":"80","author":"LLC Deak","year":"2020","unstructured":"Deak LLC, et al. RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1\/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint Inhibition to reactivate dysfunctional T cells. Cancer Res. 2020;80(16Supplement):2270\u20132270.","journal-title":"Cancer Res"},{"issue":"8","key":"1759_CR38","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.molimm.2006.09.032","volume":"44","author":"M M\u00f8lh\u00f8j","year":"2007","unstructured":"M\u00f8lh\u00f8j M, et al. CD19-\/CD3-bispecific antibody of the bite class is Far superior to tandem Diabody with respect to redirected tumor cell Lysis. Mol Immunol. 2007;44(8):1935\u201343.","journal-title":"Mol Immunol"},{"key":"1759_CR39","volume-title":"Cardio-oncology practice manual: a companion to Braunwald\u2019s Heart Disease","author":"J Herrmann","year":"2022","unstructured":"Herrmann J. Cardio-oncology practice manual: a companion to Braunwald\u2019s Heart Disease. Elsevier Health Sciences; 2022."},{"issue":"3","key":"1759_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/jnci\/djz207","volume":"112","author":"TJ Hwang","year":"2020","unstructured":"Hwang TJ, et al. Pediatric trials for cancer therapies with targets potentially relevant to pediatric cancers. JNCI: J Natl Cancer Inst. 2020;112(3):224\u20138.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"1759_CR41","doi-asserted-by":"crossref","unstructured":"Reusch U, et al. A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent Lysis of CD19\u2009+\u2009tumor cells. MAbs. Taylor & Francis; 2015.","DOI":"10.1080\/19420862.2015.1029216"},{"key":"1759_CR42","doi-asserted-by":"publisher","first-page":"p1551","DOI":"10.1007\/s00262-007-0298-z","volume":"56","author":"C Brandl","year":"2007","unstructured":"Brandl C, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell Lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother. 2007;56:p1551\u20131563.","journal-title":"Cancer Immunol Immunother"},{"key":"1759_CR43","unstructured":"Food US, Administration D. F. FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer. 2021 [cited 2024 September 24]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer"},{"issue":"1","key":"1759_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/14737140.2022.2016397","volume":"22","author":"S Vyse","year":"2022","unstructured":"Vyse S, Huang PH. Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. Expert Rev Anticancer Ther. 2022;22(1):3\u201316.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1759_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100641","author":"J Neijssen","year":"2021","unstructured":"Neijssen J, et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. 2021. https:\/\/doi.org\/10.1016\/j.jbc.2021.100641.","journal-title":"J Biol Chem"},{"key":"1759_CR46","unstructured":"FDA. FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors. 2017 [cited 2024 September 24]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii"},{"issue":"12","key":"1759_CR47","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1111\/jth.15506","volume":"19","author":"M Kaneda","year":"2021","unstructured":"Kaneda M, et al. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A. J Thromb Haemost. 2021;19(12):2938\u201346.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1759_CR48","doi-asserted-by":"publisher","first-page":"e57479","DOI":"10.1371\/journal.pone.0057479","volume":"8","author":"Z Sampei","year":"2013","unstructured":"Sampei Z, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8(2):e57479.","journal-title":"PLoS One"},{"issue":"02","key":"1759_CR49","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1055\/s-0039-3401822","volume":"120","author":"PA Cortesi","year":"2020","unstructured":"Cortesi PA, et al. Cost-effectiveness and budget impact of Emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost. 2020;120(02):216\u201328.","journal-title":"Thromb Haemost"},{"issue":"1","key":"1759_CR50","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/hae.14143","volume":"27","author":"H Lee","year":"2021","unstructured":"Lee H, et al. Cost-utility analysis of Emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea. Haemophilia. 2021;27(1):e12\u201321.","journal-title":"Haemophilia"},{"issue":"1","key":"1759_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40164-021-00250-1","volume":"10","author":"Y Wu","year":"2021","unstructured":"Wu Y, et al. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol. 2021;10(1):56.","journal-title":"Exp Hematol Oncol"},{"key":"1759_CR52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-3-030-96376-7_11","volume":"183","author":"P Hays","year":"2022","unstructured":"Hays P. Clinical development and therapeutic applications of bispecific antibodies for hematologic malignancies. Cancer Treat Res. 2022;183:287\u2013315.","journal-title":"Cancer Treat Res"},{"issue":"1","key":"1759_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou S, et al. The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021;9(1):38.","journal-title":"Biomark Res"},{"key":"1759_CR54","doi-asserted-by":"publisher","unstructured":"Lu RM, Chiang HL, Yuan JP et al. Technological advancements in antibody-based therapeutics for treatment of diseases. J Biomed Sci. 2025;32(98). https:\/\/doi.org\/10.1186\/s12929-025-01190-2.","DOI":"10.1186\/s12929-025-01190-2"},{"key":"1759_CR55","unstructured":"Grand View Research. Bispecific antibodies market size, share & trends analysis report by drug type (Immunoglobulin G, non-Immunoglobulin G), by indication (cancer, autoimmune diseases), by distribution channel (hospital pharmacies, retail pharmacies, drugstores, online pharmacies) and by region (North America, Europe, APAC, Middle East and Africa, LATAM), forecasts, 2025\u20132033. Grand View Research Report ID: ID: GVR-4-68040-088-4. (2025). Available at: https:\/\/www.grandviewresearch.com\/industry-analysis\/bispecific-antibodies-market-report."},{"issue":"1","key":"1759_CR56","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/genedge.4.1.39","volume":"4","author":"A Philippidis","year":"2022","unstructured":"Philippidis A. Learning curve: Absci, NVIDIA partner on antibody design: companies to apply Absci-developed machine learning models that predict target affinity, naturalness of sequence variants and other mAbs of interest. GEN Edge. 2022;4(1):237\u201344.","journal-title":"GEN Edge"},{"key":"1759_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-024-01195-6","author":"S Jahandar-Lashaki","year":"2024","unstructured":"Jahandar-Lashaki S, et al. Phage display as a medium for target therapy based drug discovery, review and update. Mol Biotechnol. 2024. https:\/\/doi.org\/10.1007\/s12033-024-01195-6.","journal-title":"Mol Biotechnol"},{"key":"1759_CR58","unstructured":"Loachamin G, Vanessa L. Phage display peptides: peptides mimicking natural epitopes. 2022."},{"key":"1759_CR59","unstructured":"Merch\u00e1n Mu\u00f1oz BD. Phage display technology: capabilities and applications. Universidad de Investigaci\u00f3n de Tecnolog\u00eda Experimental Yachay; 2022."},{"key":"1759_CR60","unstructured":"Moreno Sanchez D. Development of a new CHO transient expression platform for mAb Production, evaluation of novel viral episome maintenance proteins for transient gene expression. University of Kent; 2022."},{"issue":"2","key":"1759_CR61","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1039\/D0CS00310G","volume":"50","author":"SJ Walsh","year":"2021","unstructured":"Walsh SJ, et al. Site-selective modification strategies in antibody\u2013drug conjugates. Chem Soc Rev. 2021;50(2):1305\u201353.","journal-title":"Chem Soc Rev"},{"issue":"11","key":"1759_CR62","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1002\/tcr.202100054","volume":"21","author":"S Manabe","year":"2021","unstructured":"Manabe S, Yamaguchi Y. Antibody glycoengineering and homogeneous antibody-drug conjugate preparation. Chem Record. 2021;21(11):3005\u201314.","journal-title":"Chem Record"},{"issue":"2","key":"1759_CR63","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1021\/bc5004982","volume":"26","author":"P Agarwal","year":"2015","unstructured":"Agarwal P, Bertozzi CR. Site-specific antibody\u2013drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem. 2015;26(2):176\u201392.","journal-title":"Bioconjug Chem"},{"key":"1759_CR64","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jconrel.2021.12.013","volume":"341","author":"SW Fatima","year":"2022","unstructured":"Fatima SW, Khare SK. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy. J Controlled Release. 2022;341:555\u201365.","journal-title":"J Controlled Release"},{"issue":"1","key":"1759_CR65","doi-asserted-by":"publisher","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","volume":"15","author":"H Kaplon","year":"2023","unstructured":"Kaplon H, et al. Antibodies to watch in 2023. MAbs. 2023;15(1):2153410.","journal-title":"MAbs"},{"key":"1759_CR66","doi-asserted-by":"publisher","first-page":"110910","DOI":"10.1016\/j.jinorgbio.2019.110910","volume":"203","author":"E Ortega","year":"2020","unstructured":"Ortega E, et al. An erlotinib gold (I) conjugate for combating triple-negative breast cancer. J Inorg Biochem. 2020;203:110910.","journal-title":"J Inorg Biochem"},{"issue":"16","key":"1759_CR67","doi-asserted-by":"publisher","first-page":"2100876","DOI":"10.1002\/advs.202100876","volume":"8","author":"X Cheng","year":"2021","unstructured":"Cheng X, et al. Multi-functional liposome: a powerful theranostic nano\u2010platform enhancing photodynamic therapy. Adv Sci. 2021;8(16):2100876.","journal-title":"Adv Sci"},{"key":"1759_CR68","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.msec.2018.04.011","volume":"89","author":"W Yang","year":"2018","unstructured":"Yang W, et al. Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Mater Sci Engineering: C. 2018;89:328\u201335.","journal-title":"Mater Sci Engineering: C"},{"key":"1759_CR69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10616-007-9103-2","volume":"55","author":"K Mori","year":"2007","unstructured":"Mori K, et al. Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies. Cytotechnology. 2007;55:109\u201314.","journal-title":"Cytotechnology"},{"issue":"30","key":"1759_CR70","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","volume":"277","author":"RL Shields","year":"2002","unstructured":"Shields RL, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733\u201340.","journal-title":"J Biol Chem"},{"issue":"22","key":"1759_CR71","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1182\/blood.V128.22.1148.1148","volume":"128","author":"AD Cohen","year":"2016","unstructured":"Cohen AD, et al. First in human study with GSK2857916, an antibody drug conjugated to microtubule-disrupting agent directed against B-cell maturation antigen (BCMA) in patients with relapsed\/refractory multiple myeloma (MM): results from study BMA117159 part 1 dose escalation. Blood. 2016;128(22):1148.","journal-title":"Blood"},{"issue":"15","key":"1759_CR72","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Belantamab mafodotin: first approval. Drugs. 2020;80(15):1607\u201313.","journal-title":"Drugs"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01759-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01759-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01759-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:01:54Z","timestamp":1772211714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01759-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1759"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01759-6","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All authors agreed for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None\/Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial and Non-financial Interests"}}],"article-number":"22"}}